Literature DB >> 11047756

Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1.

D M Reynolds1, C T Falk, A Li, B F King, P S Kamath, J Huston, C Shub, D M Iglesias, R S Martin, Y Pirson, V E Torres, S Somlo.   

Abstract

Polycystic liver disease (PCLD) is characterized by the growth of fluid-filled cysts of biliary epithelial origin in the liver. Although the disease is often asymptomatic, it can, when severe, lead to complications requiring surgical therapy. PCLD is most often associated with autosomal dominant polycystic kidney disease (ADPKD); however, families with an isolated polycystic liver phenotype without kidney involvement have been described. The clinical presentation and histological features of polycystic liver disease in the presence or absence of ADPKD are indistinguishable, raising the possibility that the pathogenetic mechanisms in the diseases are interrelated. We ascertained two large families with polycystic liver disease without kidney cysts and performed a genomewide scan for genetic linkage. A causative gene, PCLD, was mapped to chromosome 19p13.2-13.1, with a maximum LOD score of 10.3. Haplotype analysis refined the PCLD interval to 12.5 cM flanked by D19S586/D19S583 and D19S593/D19S579. The discovery of genetic linkage will facilitate diagnosis and study of this underdiagnosed disease entity. Identification of PCLD will be instrumental to an understanding of the pathogenesis of cyst formation in the liver in isolated PCLD and in ADPKD.

Entities:  

Mesh:

Year:  2000        PMID: 11047756      PMCID: PMC1287938          DOI: 10.1086/316904

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  28 in total

Review 1.  Roles of the NFI/CTF gene family in transcription and development.

Authors:  R M Gronostajski
Journal:  Gene       Date:  2000-05-16       Impact factor: 3.688

Review 2.  Calreticulin, a multifunctional Ca2+ binding chaperone of the endoplasmic reticulum.

Authors:  M Michalak; P Mariani; M Opas
Journal:  Biochem Cell Biol       Date:  1998       Impact factor: 3.626

3.  Polycystic liver; analysis of seventy cases.

Authors:  P J MELNICK
Journal:  AMA Arch Pathol       Date:  1955-02

4.  The prevalence and characterization of simple hepatic cysts by ultrasound examination.

Authors:  P A Gaines; M A Sampson
Journal:  Br J Radiol       Date:  1989-04       Impact factor: 3.039

5.  Avoiding recomputation in linkage analysis.

Authors:  A A Schäffer; S K Gupta; K Shriram; R W Cottingham
Journal:  Hum Hered       Date:  1994 Jul-Aug       Impact factor: 0.444

6.  Expression patterns of the four nuclear factor I genes during mouse embryogenesis indicate a potential role in development.

Authors:  A Z Chaudhry; G E Lyons; R M Gronostajski
Journal:  Dev Dyn       Date:  1997-03       Impact factor: 3.780

7.  Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients.

Authors:  R A Nishimura; M D McGoon; C Shub; F A Miller; D M Ilstrup; A J Tajik
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

8.  Liver cysts in patients with autosomal dominant polycystic kidney disease.

Authors:  J Milutinovic; P J Fialkow; T G Rudd; L Y Agodoa; L A Phillips; J I Bryant
Journal:  Am J Med       Date:  1980-05       Impact factor: 4.965

9.  Impairment of drug metabolism in polycystic non-parasitic liver disease.

Authors:  E A Sotaniemi; P V Luoma; P M Järvensivu; K A Sotaniemi
Journal:  Br J Clin Pharmacol       Date:  1979-10       Impact factor: 4.335

10.  Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p.

Authors:  C Jodice; E Mantuano; L Veneziano; F Trettel; G Sabbadini; L Calandriello; A Francia; M Spadaro; F Pierelli; F Salvi; R A Ophoff; R R Frants; M Frontali
Journal:  Hum Mol Genet       Date:  1997-10       Impact factor: 6.150

View more
  25 in total

1.  Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda Page; David R Holmes; Xujian Li; Eric J Bergstralh; Maria V Irazabal; Bohyun Kim; Bernard F King; James F Glockner; Nicholas F Larusso; Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2012-07-06       Impact factor: 5.992

2.  Autosomal dominant polycystic liver disease in a family without polycystic kidney disease associated with a novel missense protein kinase C substrate 80K-H mutation.

Authors:  Ramón Peces; Joost P H Drenth; Rene H M Te Morsche; Pedro González; Carlos Peces
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Screening analysis of candidate gene mutations in a kindred with polycystic liver disease.

Authors:  Song Jin; Kai Cui; Zi-Qiang Sun; Yang-Yang Shen; Pang Li; Zhen-Dan Wang; Fei-Fei Li; Ke-Nan Gong; Sheng Li
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

4.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

Review 5.  Isolated polycystic liver disease.

Authors:  Qi Qian
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

6.  Activation of Trpv4 reduces the hyperproliferative phenotype of cystic cholangiocytes from an animal model of ARPKD.

Authors:  Sergio A Gradilone; Tatyana V Masyuk; Bing Q Huang; Jesus M Banales; Guillermo L Lehmann; Brynn N Radtke; Angela Stroope; Anatoliy I Masyuk; Patrick L Splinter; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2010-04-14       Impact factor: 22.682

7.  A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.

Authors:  Sorin V Fedeles; Xin Tian; Anna-Rachel Gallagher; Michihiro Mitobe; Saori Nishio; Seung Hun Lee; Yiqiang Cai; Lin Geng; Craig M Crews; Stefan Somlo
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

8.  Chromosomal abnormalities in hepatic cysts point to novel polycystic liver disease genes.

Authors:  Edgar S Wills; Wybrich R Cnossen; Joris A Veltman; Rob Woestenenk; Marloes Steehouwer; Jody Salomon; René H M Te Morsche; Meritxell Huch; Jayne Y Hehir-Kwa; Martijn J Banning; Rolph Pfundt; Ronald Roepman; Alexander Hoischen; Joost P H Drenth
Journal:  Eur J Hum Genet       Date:  2016-08-24       Impact factor: 4.246

Review 9.  Surgical management of polycystic liver disease.

Authors:  Robert T Russell; C Wright Pinson
Journal:  World J Gastroenterol       Date:  2007-10-14       Impact factor: 5.742

10.  Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.

Authors:  Myrte K Neijenhuis; Tom J G Gevers; Marie C Hogan; Patrick S Kamath; Titus F M Wijnands; Ralf C P M van den Ouweland; Marie E Edwards; Jeff A Sloan; Wietske Kievit; Joost P H Drenth
Journal:  Hepatology       Date:  2016-04-15       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.